Seeking Alpha

UBS thinks data from a Phase III study will "suggest a greater magnitude of overall survival...

UBS thinks data from a Phase III study will "suggest a greater magnitude of overall survival benefit" for Medivation's (MDVN) Xtandi than for Janssen's (JNJ) Zytiga. Analyst Matthew Roden upgrades MDVN to Buy and hikes his price target to $74 from $59.
Comments (3)
  • This is a no-brainer. UBS' Matthew Roden is to be congratulated (not). The fact is, Zytiga demonstrated NO statistically significant overall survival benefit whatsoever in the prechemo environment. The only primary endpoint it met in the Phase 3 trial was for progression free survival (PFS). Anything Xtandi demonstrates in the way of a stat sig OS would be better than Zytiga's...which was ZERO.
    17 Jul 2013, 08:35 AM Reply Like
  • Most medicines you can consider yourself lucky, if they have no effect. My father in law has to take 15 different pills every day. Sometimes I think he would be better of taking none!!
    17 Jul 2013, 09:58 AM Reply Like
  • I'm sorry for your father-in-law's proglrms. The fact is, in the prechemo environment, there is, today, only one treatment that has demonstrated a statistically significant MEDIAN overall survival benefit (4.1 months) for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer. The treatment is Provenge.
    17 Jul 2013, 10:30 AM Reply Like
DJIA (DIA) S&P 500 (SPY)